RE: Rumblings of a takeover20 Jun 2021 13:26
Hi sad. Agree. Any company that is looking ar sareum for a while, will now be paying more attention as the covid19 situation has changed things. If and when it goes into agile , and as I expect the results to be very good as it is not toxic and does what it says on can. If tyk2 gets fast tracked into market ,the revenue stream will be amazing. If you think nonsense....look at other companies that have cracked this nut....
Any company that awaits covid19 results will have a problem, as overnight sareum will go from minnow to a good sized beast. That changes things....as the shoe then goes onto the other foot....
The fact that another indication respiratory patented....with all chaos last year.....the money being given by our lovely donor.....the tweets.....the boards previous positive statements, the facy that similar dirtier drugs that are not effective being utilised.....imagine this walks in and says hiiiiii....
I said a long time, let the science talk....but the louder it talks, the louder will get our geeky scientists and the more expensive it will get to prize this away from their hands.
I still said bugger all about chk1,tyk2 autoimmune, cancer.
Interesting times......